Novavision, Inc.

Other

Massachusetts Institute of Technology

Ebs Technologies Gmbh

Nanodel Technologies Gmbh

Medinova Medical Consulting Gmbh

Novavision Ag

Bernhard A Sabel

Andrew Freese

David P Todd

Jorg Kreuter

William Mark Saltzman

Dimitri A Karkevich

Christian Walz

Iris Müller

Kerstin Ringe

Renad N Alyautdin

Ulrike Schroeder

Matthew J During

Tobias Günther

William M Saltzman

Erich Kasten

Tobias GÜNTHER

The present invention relates to an apparatus for automatic adjustment of a treatment of a target person to be treated based on calculated recovery prediction data for predicting a change of a sensory function of said target person in response to said treatment.

Apparatus and a method for automatic treatment adjustment after nervous system dysfunction

An apparatus for stimulating a brain (B) of a person () comprising a detector () for detecting an induced or a spontaneous physiological signal generated by the brain (B), a control unit () being connected to said detector () for comparing the detected physiological signal with a criterion to determine an optimal setting of a variable signal parameter, a first signal generator () for applying an electrical stimulation signal (EES) to said person () and/or at least one second signal generator () for applying a sensory stimulation signal (SSS) to a sensory organ (A) of said person (), wherein a signal parameter of the stimulation signals (ESS, SSS) are adjusted to the determined optimal setting of said signal parameter.

Apparatus and method for stimulating a brain of a person

A training device for training at least one user comprising a user output interface () for presenting at least one training task (t) to said user (), a user input interface () for inputting a response of said user () to each presented training task (t), means () for detecting a performance (p) of said user () on the basis of the responses input by said user (), and means () for presenting rewards for the detected performance (p) of said user, wherein said rewards are selected depending on a training date (TD) on which the responses are input by said user () and depending on an age (A) of said user ().

Method and device for training of a user

A device and method are provided for treating the visual system of a human including the retina, visual cortex and/or other neuro-cellular structures. The method includes the steps of locating and defining a blind zone of deteriorated vision within the human's visual system, defining a treatment area which is located predominantly within the blind zone, and treating the human's visual system by presenting visual stimuli to the human's visual system. The majority of the visual stimuli are presented to at least a portion of the blind zone.

Process and device for treating blind regions of the visual field

Systems and methods for treating a retinal disease in a human include locating and defining one or more zones of vision within the human's visual system and defining a treatment area which is located within at least one of the zones. The method of this embodiment may also include treating the human's retinal disease by presenting visual stimuli to the treatment area at a specified location and with a specified definition and recording changes in specified characteristics of the human's visual system. The method of this embodiment may also include reiterating the previous steps so as to improve the human's overall visual system.

System and methods for the treatment of retinal diseases

A head-guide for diagnosing or training vision of a user and methods of user thereof are disclosed. The head-guide may include a head-support for orienting a head of the user, a display-support for orienting a display. The head-guide may also include a guide-support connected to the head-support and the display-support. The head-support and display-support may be pre-configured to fix the relative position of the head and the display and the display may present visual stimuli to diagnose or train the vision of the user.

Method and device for guiding a user's head during vision training

The invention relates to the use of DNA-loaded nanoparticles for a transfection of DNA into cells in vitro or in vivo.

Use of nanoparticles for the DNA administration to a target organ

The present invention relates to a process for training the visual system of a human by presenting optical stimuli to said human, said stimuli being presented to a zone within the intact visual field of said human and optionally to a zone outside the intact visual field of said human, one of said zones comprising a zone to be trained, thereby allowing an improvement of the vision in general, said process comprising the steps of (a) locating and defining a zone of intact vision and optionally a zone of deteriorated vision or residual visual function or partial visual system injury ('transition zone') within the human's visual system; (b) defining a training area which is located within at least one of said zones including the zone of intact vision; (c) training the human's visual system by presenting visual stimuli to the human's visual system, at least a part of said visual stimuli being presented in or near said zone of intact vision; (d) recording changes in the characteristics of the human's visual system; (e) adapting the location and definition of the stimulus presentation to said at least one zone, including the zone of intact vision, according to said changes; and (f) reiterating the previous steps continuously so as to improve the human's overall visual system. The invention also relates to a device for performing said process.

Process and device for the training of human vision

A composition and method of fabrication are presented with which nanoparticles may be used as a tool to deliver drugs to a specific target within or on a mammalian body. Specifically, by using stabilizers other than Dextran 70.000 during the polymerization process, according to the present invention, surfactants, which were deemed necessary coating material in the prior art, are no longer required. This is a significant simplification of the fabrication procedure. Many substances are useful as stabilizers, but the preferred stabilizers comprise Dextran 12.000 or polysorbate 85. In the present invention a drug is either incorporated into or adsorbed onto the stabilized nanoparticles. This drug/nanoparticle complex is then administered to the organism on any route such as by oral application, injection or inhalation, whereupon the drug exerts its effect at the desired site of pharmacological action. In a novel medical treatment process, the drug/nanoparticle complex may be administered preferably either by intravenous injection or by oral application. The resulting drug action, which does not occur or which occurs only to an insufficient extent when the drug is administered alone, shows that when linked to said nanoparticles drugs can reach a specific target within or on the mammalian body. The usefulness of the present invention as a universal approach to deliver any drug or diagnostic agent to a specific target within or on the mammalian body was demonstrated by experiments showing an unexpected transfer of the drug across the blood brain barrier.

Drug targeting system, method of its preparation and its use

The present invention concerns a process for training the visual system of a human by presenting optical stimuli to said human, said stimuli being presented to a zone within the intact visual field of said human and to a zone outside the intact visual field of said human, the latter zone comprising a zone to be trained, thereby allowing an improvement of the vision in said latter zone, said process comprising the steps of locating and defining a zone of deteriorated vision or residual visual function or partial visual system injury (&ldquo;transition zone&rdquo;) within the human's visual system; defining a training area which is located within said transition zone; training the human's visual system by presenting visual stimuli to the human's visual system, the majority of said visual stimuli being presented in or near said transition zone; recording changes in the characteristics of the human's visual system; adapting the location and definition of the stimulus presentation to said transition zone according to said changes; and reiterating the previous steps continuously so as to extend the human's intact visual field into said transition zone and said transition zone into a zone of more deteriorated vision or a zone of less residual visual function or a zone of substantially complete visual system injury, and a device for conducting said process.

A novel method of delivering drugs and diagnostics across the blood-brain barrier or blood-nerve barrier is disclosed. Drugs or diagnostic agents are incorporated into nanoparticles which have been fabricated in conventional ways. These nanoparticles are then coated with additional surfactant and given to the body of animals or humans. This allows drugs or diagnostic agents to cross the blood-brain barrier (bbb) to achieve one or more of the following benefits: (1) reducing the dose of a therapeutic drug or diagnostic agent which, when given peripherally, maintains the biological or diagnostic potency in the nervous system, (2) allowing drugs that normally do not cross the bbb to penetrate into the nervous system, and (3) reducing the peripheral side effects by increasing the relative amount of the drug reaching the brain.

Drug targeting to the nervous system by nanoparticles

Disclosed is a polymeric drug delivery system for delivery of any substance to the central nervous system. The delivery system is preferably implanted in the central nervous system for delivery of the drug directly to the central nervous system. These implantable devices can be used, for example, to achieve continuous delivery of dopamine, which cannot pass the blood brain barrier, directly into the brain for an extended time period. The implantable devices display controlled, 'zero-order' release kinetics, a life time of a minimum of several weeks or months even when the devices contain water soluble, low molecular weight compounds, biocompatibility, and relative non-invasiveness. The polymeric devices are applicable in the treatment of a variety of central nervous system disorders including Parkinson's disease, Alzheimer's dementia, Huntington's disease, epilepsy, trauma, stroke, depression and other types of neurological and psychiatric illnesses.

Polymeric device for controlled drug delivery to the CNS

A polymeric device releasing biologically active, water-soluble materials having a molecular weight of less than 1000 in a controlled, continuous and linear manner over an extended period of time. Insoluble polymer matrixes can be defined in any shape, size and drug content. When applied to medical use, biocompatible polymers are used so that the device is implantable. The device is made by modifying prior art devices based on diffusion of fluid into a polymeric matrix containing dispersed biologically active molecules to yield a polymer device which can be placed in a fluid environment, so that fluid is absorbed by the device and the water soluble molecules diffuse into the fluid environment, leaving behind pores and channels, where the rate of diffusion is limited by an impermeable coating over a portion of t

Extended drug delivery of small, water-soluble molecules

The present invention is a method and composition for treatment of ischemic, metabolic, congenital, or degenerative disorders of the central or peripheral nervous system. The composition is formed by encapsulation within an implantable biocompatible polymeric device of one or more compounds which have the effect or replacing or stimulating functions of the nervous system. A variety of biocompatible polymers including both biodegradable and non-degradable polymers can be used to form the implants. An essential feature of the composition is linear release, achieved through manipulation of the polymer composition and form. The selection of the shape, size, drug, polymer, and method for implantation are determined on an individual basis according to the disorder to be treated and the individual patient response. A plethora of neurally active substances can be used to treat or manipulate neurological disorders, including Parkinson's Disease, particularly the subset which is refractory or poorly responsive to existing therapies; Alzheimer's Disease; Huntington's Disease; and trauma, such as spinal cord injury.

Growing community of inventors

Berlin, Germany

Bernhard A Sabel